Rosacea 환자에서 BMX-010의 국소 적용 평가
Rosacea가 있는 피험자에서 BMX-010의 국소 적용의 임상적 효과를 평가하기 위한 탐색적 시험
This is an exploratory Phase 2 trial of BMX-010 in patients with Rosacea which will be conducted in two parts. Up to 210 subjects with Rosacea will be enrolled.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Part A is designed to confirm the optimal formulation, strength, and dosing frequency of the study drug. Up to 60 subjects will be enrolled in this part.
Part B is designed to be a randomized, double-blind trial studying the optimal formulation, strength, and dosing frequency of BMX-010 as determined in Part A, compared to Placebo. Up to 150 subjects will be enrolled in this part.
In both parts, adult subjects with Rosacea will be enrolled.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Colorado
-
Englewood, Colorado, 미국, 80113
- Colorado Skin Care
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female, at least 18 years of age;
- A clinical diagnosis of mild to severe facial rosacea;
- Screening and Baseline IGA score > 2 (greater than or equal to 2);
- A minimum Clinician Erythema Assessment (CEA) score of 2 at Screening and at Baseline Visits (prior to the investigational product application);
- Willing to refrain from using any topical or systemic treatments for inflammatory skin disease, other than the investigational product;
- Candidate for topical treatment of Rosacea;
- If a cleanser, moisturizer or sunscreen is needed during the study, Subjects must be willing to use only allowed cleansers, moisturizers, sunscreens, or moisturizer/sunscreen combination products. If the subject wears makeup they must agree to use non-comedogenic makeup;
- Females of child-bearing potential must have a negative urine pregnancy test within 48 hours prior to the first drug administration;
- Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the investigator (for example, oral contraceptive pills plus a barrier method) through the trial and for 1 month thereafter to be eligible for, and continue participation in, the study;
- Ability to complete the study in compliance with the protocol, including agreement in writing to apply study product only to the assigned areas; and
- Ability to understand and provide written informed consent.
Exclusion Criteria:
- Any dermatological conditions on the face that could interfere with clinical evaluations;
- Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive;
- Presence of beard or excessive facial hair at Screening which would interfere with the study treatments or study assessments and refusal to remove for duration of study;
- Subjects with any underlying disease that the Investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study;
- Concomitant skin disease that could confound clinical evaluations or increase risk to the subject;
- Use of medicated make-up (including anti-aging make-up) throughout the study;
- Use during the study of 1) systemic steroids, 2) topical retinoids to the face, 3) antibiotics known to impact rosacea, 4) immunosuppressive agents, or immunomodulators;
- Facial use of 1) topical steroids, 2) topical anti-inflammatory agents, 3) topical antimycotics, 4) any topical rosacea treatments or 4) topical antibiotics;
- Use of medicated cleansers on the face (throughout the study);
- Use of topical astringents or abrasives, medical topical preparations (prescription and OTC products) within 2 days prior to Baseline and throughout the study;
- Systemic or skin infection requiring antimicrobial therapy;
- Systemic chemotherapy or radiotherapy within 4 weeks of the Baseline Visit;
- Immunocompromise of any cause, known human immunodeficiency virus infection, or acquired immunodeficiency syndrome;
- Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the investigator;
- Active drug or alcohol dependence;
- Significant acute or chronic medical, neurological, or psychiatric illness that, in the judgment of the investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study;
- Previous clinical trial participation for the indication being treated in this protocol.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: BMX-010 0.03%
Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Rosacea of the face. |
Safety and efficacy of BMX-010 in topical treatment of rosacea. |
|
실험적: BMX-010 0.1%
Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Rosacea of the face. |
Safety and efficacy of BMX-010 in topical treatment of rosacea. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Investigator Global Assessment (IGA) Grade: Clinically Meaningful Rosacea Treatment Success Rate
기간: 43 days
|
The percentage of subjects will be reported that experience a clinically meaningful treatment success, which is defined as a 2-point reduction in Investigator Global Assessment (IGA) grade from the baseline assessment prior to treatment to the final assessment two weeks after dosing ends (Day 43). |
43 days
|
|
Clinical Erythema Assessment (CEA): Clinically Meaningful Erythema Reduction Rate
기간: 43 days
|
Assessed by number of participants with at least a 2-point reduction in Clinical Erythema Assessment (CEA) grade from the baseline score prior to treatment to a final assessment two weeks after dosing ends (Day 43). |
43 days
|
|
Investigator Global Assessment (IGA) Grade: Rosacea Severity Change Over Treatment Period
기간: 28 days
|
The Investigator Global Assessment (IGA) grade, which will be assessed weekly, is a clinical assessment of disease severity. Scores range from 0 (clear) - 4 (severe). The change in IGA score from Baseline to 28 days of treatment will be reported. |
28 days
|
|
Clinical Erythema Assessment (CEA): Erythema Severity Change Over Treatment Period
기간: 28 days
|
The Clinical Erythema Assessment (CEA) grade will be assessed weekly. Grades range from 0 = clear/no erythema to 4 = severe/fiery red erythema. The change in CEA score from Baseline to 28 days of treatment will be reported. |
28 days
|
|
Investigator Global Assessment (IGA) Grade: Clinically Meaningful Rosacea Reduction During Treatment
기간: 28 days
|
The percentage of subjects will be reported that experience a clinically meaningful rosacea reduction, which is defined as a 2-point reduction in Investigator Global Assessment (IGA) grade over the treatment period of 28 days. |
28 days
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Clinical Photography Documenting Rosacea Symptoms in Patients Treated With BMX-010
기간: 43 days
|
If consented by the patient, photos will be taken at each study visit. The number of patients photographed will be reported. |
43 days
|
|
Change in Number of Inflammatory Papules/Pustules From Baseline to 43 Day Follow-up.
기간: 43 days
|
Inflammatory lesions will be counted at each study visit. The mean percent change in inflammatory papules/pustules counts from baseline to the final (day 43) follow-up will be reported. |
43 days
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- BMX-DERM-202
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .